SCHEMBL3230779

SCHEMBL3230779

NC(=O)C1=C(CO)c2cc(F)ccc2[N]1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.35
PARP1 P09874 1/20 0.34
CHEK2 O96017 2/20 0.34
RXRA P19793 1/20 0.34
GRM2 Q14416 4/20 0.33
KEAP1 Q14145 1/20 0.33
IKBKB O14920 1/20 0.33
CHUK O15111 1/20 0.33
CDC7 O00311 1/20 0.32
PLK4 O00444 1/20 0.32
DAPK3 O43293 1/20 0.32
PRKD3 O94806 1/20 0.32
MAP4K4 O95819 1/20 0.32
CDK1 P06493 1/20 0.32
FES P07332 1/20 0.32
ROS1 P08922 1/20 0.32
PIM1 P11309 1/20 0.32
FGFR1 P11362 1/20 0.32
FER P16591 1/20 0.32
PRKACA P17612 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3222543 0.82 NR3C1 (0.34) PPARGRXRAGRM2SCN9ASLC9A1
SCHEMBL3226166 0.80 MAPK14 (0.34) PPARGRXRAGRM2SCN9ASLC9A1
SCHEMBL3261767 0.80 PARP1 (0.37) PARP1CHEK2GRM2KEAP1IKBKB
SCHEMBL3217914 0.78 GRM2 (0.37) PPARGPARP1CHEK2GRM2KEAP1
SCHEMBL3231611 0.78 SLC9A1 (0.38) PPARGPARP1RXRAGRM2KEAP1
SCHEMBL3213498 0.76 GRM2 (0.48) GRM2
SCHEMBL3233045 0.76 PARP1 (0.34) PARP1CHEK2GRM2KEAP1PLK4
SCHEMBL3232086 0.75 USP8 (0.35) PARP1CHEK2GRM2KEAP1PLK4
SCHEMBL14312925 0.71 SLC9A1 (0.35) IKBKBCHUKSLC9A1
SCHEMBL14313892 0.71 SLC9A1 (0.38) IKBKBCHUKSLC9A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP claimed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US claimed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US claimed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP claimed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO claimed
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US disclosed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 PPARG 396/4885PARP1 295/4885CHEK2 1977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.